Get the Stockscreener App
2.03
5.18%
0.10
Pre-market:
2.08
0.05
+2.46%
Milestone Pharmaceuticals Inc stock is traded at $2.03, with a volume of 2.36M.
It is up +5.18% in the last 24 hours and down -11.35% over the past month.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
See More
Previous Close:
$1.93
Open:
$2
24h Volume:
2.36M
Relative Volume:
2.80
Market Cap:
$108.26M
Revenue:
-
Net Income/Loss:
$-59.69M
P/E Ratio:
-1.4604
EPS:
-1.39
Net Cash Flow:
$-46.54M
1W Performance:
+6.84%
1M Performance:
-11.35%
6M Performance:
+33.55%
1Y Performance:
+40.00%
1-Day Range:
$1.955
$2.17
1-Week Range:
$1.75
$2.17
52-Week Range:
$1.12
$2.75
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
Name
Milestone Pharmaceuticals Inc
Sector
Industry
Phone
(514) 336-0444
Address
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Compare MIST with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
2.03 | 108.26M | 0 | -59.69M | -46.54M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Jun-20-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-22-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-05-21 | Initiated | H.C. Wainwright | Buy |
| Jul-29-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-24-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-25-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-24-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-24-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-04-19 | Initiated | Oppenheimer | Outperform |
| Jun-03-19 | Initiated | Cowen | Outperform |
| Jun-03-19 | Initiated | Jefferies | Buy |
| Jun-03-19 | Initiated | Piper Jaffray | Overweight |
View All
Milestone Pharmaceuticals Inc Stock (MIST) Latest News
Milestone Pharmaceuticals Eyes FDA Approval for CARDAMYST - TipRanks
Milestone Pharmaceuticals Awaits FDA Decision on CARDAMYST, Prepares for Mid-2025 Launch - TipRanks
Milestone Pharmaceuticals: Q4 Earnings Snapshot - CTPost
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update - The Manila Times
Milestone Pharmaceuticals Inc Full Year Loss Decreases, But Misses Estimates - Nasdaq
Milestone Pharmaceuticals Inc. SEC 10-K Report - TradingView
Milestone Pharmaceuticals (MIST) Projected to Post Quarterly Earnings on Thursday - Defense World
Sun Pharma to acquire Checkpoint Therapeutics for $355 million in cash and milestone payments - CNBCTV18
Best Biotech Stocks to Buy in 2025 - The Motley Fool
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Milestone Pharmaceuticals Awards 94,000 Stock OptionsWhat This Means for Shareholder Value - StockTitan
Milestone Pharmaceuticals’ (MIST) “Buy” Rating Reiterated at HC Wainwright - Defense World
Can Milestone Pharma's Trial Data Of Etripamil Nasal Spray In AFib-RVR Win Investors' Hearts? - RTTNews
US FDA’s March Approval Candidates Take Aim At Established Markets - Citeline News & Insights
Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference - The Manila Times
When Can Investors Hear Milestone Pharma's Next Strategic Update? Key Conference Date Revealed - StockTitan
Milestone Pharmaceuticals Prepares for CARDAMYST Launch - TipRanks
NLS Pharmaceutics and Partners Achieve Milestone in Diabetes Treatment Development - MSN
Milestone Pharmaceuticals Gets Notice of Allowance for US Patent on Etripamil Nasal Spray - Marketscreener.com
Milestone Pharmaceuticals secures key patent for CARDAMYST By Investing.com - Investing.com South Africa
Milestone Pharmaceuticals secures key patent for CARDAMYST - Investing.com India
Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil - The Manila Times
Milestone receives notice of allawance from USPTO on etripamil nasal spray - TipRanks
Short Interest in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Declines By 27.9% - MarketBeat
Adversity is less terrifying than hope: Milestone Pharmaceuticals Inc (MIST) - SETE News
AGIOS PHARMACEUTICALS, INC. SEC 10-K Report - TradingView
MISTMilestone Pharmaceuticals Latest Stock News & Market Updates - StockTitan
Neuphoria Therapeutics to receive $15M milestone payment from Merck - MSN
Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck - Yahoo Finance
Milestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025 - The Manila Times
Milestone's CARDAMYST Launch Roadmap: Key Details Coming for $1B PSVT Market Opportunity - StockTitan
Retail investors who hold 57% of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) gained 14%, institutions profited as well - Simply Wall St
Milestone Pharmaceuticals Inc (MIST) may enjoy gains as insiders got busy in the recent days - Knox Daily
Milestone Pharmaceuticals Inc (MIST) Stock: A Closer Look at the Analyst Ratings - The News Heater
Milestone Pharmaceuticals Inc (MIST) Stock: A Year of Highs and Lows - The InvestChronicle
Conduit's AI-Powered Drug Development Takes Major Leap: Real-Time Trial Dashboard Unveiled - StockTitan
BlackRock, Inc. Reduces Stake in Milestone Pharmaceuticals Inc - GuruFocus.com
What was Milestone Pharmaceuticals Inc (MIST)’s performance in the last session? - US Post News
Insider’s View: Deciphering Fangdd Network Group Ltd (DUO)’s Financial Health Through Ratios - The Dwinnex
Loss-Making Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Expected To Breakeven In The Medium-Term - Yahoo Finance
What is HC Wainwright's Forecast for MIST FY2029 Earnings? - MarketBeat
HC Wainwright Analysts Decrease Earnings Estimates for MIST - MarketBeat
More Heart, Less Skin: US FDA’s 2025 Novel Approvals Should Reflect Pipeline Shifts - Citeline News & Insights
Vertex’s non-opioid pain drug gets FDA approval in milestone for company and research - BioPharma Dive
HC Wainwright Has Pessimistic Outlook of MIST Q1 Earnings - Defense World
Innocan Pharma's Subsidiary BI Sky Global Completes HRIPT Testing and Surpasses Important Sales Milestone - PR Newswire
Milestone Pharma Faces FDA Decision In MarchWill It Mean Heartbreak Or Happiness For Investors? - RTTNews
FY2029 Earnings Estimate for MIST Issued By HC Wainwright - Defense World
Jaguar Health Provides Corporate Update and Outlines 2022 Milestones - ACCESS Newswire
Milestone gears up for CARDAMYST launch in 2025 By Investing.com - Investing.com Australia
Milestone gears up for CARDAMYST launch in 2025 - Investing.com
Milestone Pharmaceuticals Inc Stock (MIST) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):